ESMO Congress 2023 | OncologyPRO

Abstract 425P

Background

Palbociclib, ribociclib and abemaciclib play an important role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) BC based on their impressive efficacy; however, there seem to be some differences in toxicity profiles which can adversely affect their QoL. This study aims to evaluate health-related QoL (HRQoL) in advanced BC patients treated with CDK4/6i with the help of digital apps.

Methods

HRQoL was assessed in women with HR+/HER2- metastatic BC treated with CDK4/6i plus endocrine therapy using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire via online platform in Spanish patients with a cut-off date of August 2022.

Results

A total of 264 patients were analyzed. 85% had between 40-69 years. 30% were employed. The most used CDK4/6i was palbociclib (46.2%), followed of ribociclib (39.8%) and abemaciclib (14%). 33% had a dose reduction. 69.7% of patients had received chemotherapy previously; of these, 91.8% consider that their QoL is better with CDK4/6i. Of all patients who are undergoing with CDK4/6i, 87.5% feel content with the treatment. Overall scores from the FACT-B questionnaire were comparable between all CDK4/6i (Table). Notably, 45.9% and 37.8% of patients in the abemaciclib group reported diarrhea and nausea, respectively. Better scores were registered in the palbociclib arm for fatigue, pain, insomnia and better sexual enjoyment. Table: 425P

FACT-B*	Palbociclib	Ribociclib	Abemaciclib	p value
N (%)	122 (46.3%)	105 (39.7%)	37 (14%)
Age (%)≤ 39 years40-69 years≥ 70 years	11 (9.02%)105 (86.07%)6 (4.92%)	14 (13.33%)89 (84.76%)2 (1.91%)	7 (18.98%)30 (81.08%)0	0,232
Physical well-being, median (range)	22 (4-28)	21 (1-28)	20 (9-27)	0,431
Social/family well-being, median (range)	17 (0-27)	18 (0-24)	18 (5-26)	0,48
Emotional well-being, median (range)	14 (3-24)	10 (0-18)	13 (6-20)	0,005
Functional well-being, median (range)	13.5 (0-26)	14 (1-27)	13 (1-23)	0,855
Breast cancer subscale, median (range)	24 (7-39)	23 (4-35)	20 (13-32)	0,027
Total score, median (range)	90 (24-135)	86 (29-127)	83 (53-104)	0,049

*Higher scores indicate a better QoL.

Conclusions

The CDK4/6i play an eminent role in the therapy of advanced BC; nevertheless, the impact of treatment in QoL should be considered in addition to efficacy and safety, especially in the non-curative setting. Our HR-QoL results seems to confirm those obtained in clinical trials. To our knowledge this is the first study about HR-QoL in HR+/HER2- BC patients treated with CDK4/6i in Spanish real-world setting.